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CRITICAL READING OF CLINICAL STUDIES. PRACTICAL
BASES FOR THE RESIDENT PHYSICIAN IN MEDICAL
SPECIALTIES
LECTURA CRÍTICA DE ESTUDIOS CLÍNICOS. BASES PRÁCTICAS PARA EL MÉDICO
RESIDENTE DE ESPECIALIDADES CLÍNICAS
Rafael Pichardo-Rodriguez1, 2, Liz B. Cordova-Cueva3, Marcos Saavedra-Velasco1
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ABSTRACT
Critical reading from the point of view of evidence-based medicine is a structured reading that allows us
to evaluate the validity and relevance of the results and the applicability of a clinical study in our patient.
However, the level of critical reading among residents is low, as described in a number of studies. A
study of oncology residents revealed an inadequate level of critical reading of clinical research articles.
Similarly, inadequate levels were observed among residents of cardiology and family practice. In our
country, this situation is unknown and it is most likely deficient. For this reason, we have prepared a
small review in order to share practical bases to help the resident of medical specialties to apply in a
simpler way the critical reading of clinical studies.
Key words: Reading; Evidence based medicine; Internship and Residence (source: MeSH NLM).

RESUMEN
La lectura crítica desde el punto de vista de la medicina basada en la evidencia es una lectura
estructurada que nos permite evaluar la validez y pertinencia de los resultados y la aplicabilidad de un
estudio clínico en nuestro paciente. Sin embargo, el nivel de lectura crítica en los médicos residentes
es baja, como se ha descrito diversos estudios. En un estudio realizado en médicos residentes de
oncología, se encontró un nivel deficiente de lectura crítica de artículos de investigación clínica. Y de
la misma forma, se encontró niveles deficientes en residentes de cardiología y medicina familiar. En
nuestro país, se desconoce esta situación y lo más probable es que sea deficiente. Motivo por el que
elaboramos una pequeña revisión para poder compartir bases prácticas que ayuden al residente de
especialidades clínicas aplicar de una manera más sencilla la lectura crítica de estudios clínicos.
Palabras clave: Lectura; Medicina Basada en la Evidencia; Internado y Residencia (fuente: DeCS BIREME).
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INTRODUCTION
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Evidence-based medicine (EBM) is a judicious way
of practicing medicine and proposes that, in order
to apply the best evidence for patient care, clinical
research articles be assessed comprehensively, as
well as taking into account the physician's experience
and the patient's preferences. Evidence-based
medicine is carried out following 5 fundamental
steps: formulation of the clinical question, search for
evidence, critical reading, application of the results
and evaluation of the impact on the patient(1,2).
Its application and teaching in our country are still
limited, and the situation of critical reading, an
essential element of the EBM, is of great concern.
Its current level is unknown, particularly among
training professionals who make decisions regarding
patient care. In addition, there are a huge number of
scientific papers published each month in high- and
low-impact journals. This makes it almost impossible
for the doctor to read all the information available on
a certain subject of interest(2,3). To do so, the physician
must perform an adequate critical reading to select
the articles relevant to their clinical expertise and
determine what article is appropriate for applying
results in patient care and whether it is worthwhile
to read more(2).
However, among physicians in training as medical
specialists or residents, critical reading is low, as
shown by a study published by Gonzáles-Ávila et
al4, carried out in oncology residents, where an
insufficient level of critical reading of clinical research
articles was found. On the other hand, Amanda Galli
et al5, in another study conducted in 169 cardiology
residents, found similar results, concluding that
the critical reading ability of young professionals is
insufficient. Similarly, in a study of family medicine
residents at Aguascalientes, they found a low critical
reading of clinical research papers(6).
As can be seen, there is a lack of knowledge of critical
reading among resident physicians and there is still
a long way to go in its teaching. For this reason, we
conducted the present review to provide practical
bases to help the resident physician in medical
specialties to apply critical reading of clinical studies
in a simpler way.

WHAT IS CRITICAL READING OF
CLINICAL STUDIES?
From the point of view of EBM, critical reading is a
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structured and systematic reading that allows us
to assess the validity and relevance of the results
and their applicability to the management of our
patient(7). In other words, critical reading responds to
three fundamental questions: Are the results valid?
What were the results? How do I apply them to my
patient?(7).

HOW TO APPROACH A CLINICAL
STUDY FOR CRITICAL APPRAISAL?
In order to address the critical reading of a clinical
study, a series of guidelines should be considered.
We recommend that clinicians follow the steps of
the Red CASPe (Critical Appraisal Skills Programme
en Español) as their recommendations are focused
on the clinical field. These three basic questions must
be answered:
1. Are the results valid?
2. What were the results?
3. How do I apply them to my patient?
In the following, we provide a practical description
of each stage of critical reading that we will develop
during the review:
• Validity assessment: We will review the most
practical way to critically approach the validity of
the evidence based on the study design and the
methodological tools we can apply.
• Evaluation of findings: We will review the findings
and evaluate their clinical impact, as well as clinical
relevance on statistical significance.
• Application of the results: We will describe the
steps to follow to apply the results of the evidence
to our patient.

VALIDITY ASSESSMENT: TYPE OF
STUDIES AND CLINICAL TOOLS
First, it is important to determine what type of clinical
question you want to answer with the study to be
evaluated and whether the design is appropriate to
answer that question. Table 1 describes the types of
clinical questions and the most appropriate research
designs to answer them. We must not forget that if
we move to a secondary design as described in Table
1, there is a higher risk of bias and a lower quality
of evidence. As a result, we cannot make the best
decisions for the health of our patients. The clinical
research question lies in the purpose of the article.

2

Pichardo-Rodriguez et al.: Critical reading of clinical studies. Practical bases forCritical
the res
reading of clinical studies

Rev. Fac. Med. Hum. 2021;21(3):623-630.

Table 1. Types of studies and suitable designs for the type of question.
Clinical
question

Main study design

Diagnosis

In patients with acute
respiratory symptoms
Is the stool antigen test
valid in relation to the
nasopharyngeal swab
for the diagnosis of COVID-19?

Statistical test of
relevance

Case-control study

Odds Ratio, Logistic
regression

Cross-sectional
study

Operational characteristics of diagnostic tests (sensitivity,
specificity, positive
and negative predictive values, positive and negative likelihood ratios, area
under the curve).

In patients diagnosed
with urosepsis, is the
Therapy and/or application of vitamin C
prevention
safe and effective in relation to placebo to reduce days in hospital?

Clinical Trial,
Systematic Review
of Clinical Trial

Prognosis

In patients diagnosed
with pneumonia caused
by COVID-19, does the
neutrophil-lymphocyte
ratio above 3 predict severity at 7 days of hospitalization?

Prospective cohort
study

Cost

In critically ill patients
diagnosed with COVID-19-related pneumonia, is the use of 6 mg IV
dexamethasone every
24 hours cost-effective
compared to placebo for
mortality reduction?

Cost-effectiveness
studies. Systematic
reviews of costeffectiveness
studies.

Retrospective
studies

REVIEW ARTICLE

Etiology

Among overweight patients, what are the factors that increase the risk
of developing an acute
myocardial infarction within five years?

Secondary study
design

Relative risk, absoluCohort studies,
te risk reduction and
Case-control studies number needed to
treat

Case-control study

Logistic regression

Cost-effectiveness
analysis, Cost-utility,
Cost minimization

Source: Elaborated by the authors. The clinical questions described are fictional questions, not actual cases. They are only an example of
formulation.
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It is important to briefly define what a clinical
question is. The clinical question is a patient-centred
question, which means that when answered,
decisions can be made for patient management(7). In
addition, depending on their syntax, they may have
two types, structured and unstructured(7). Table 2
sets out the differences between a structured clinical

Pichardo R et al

question and an unstructured clinical question. The
clinician should ask patient-centred and structured
questions, as this will help him/her to systematize
more effectively the problem he/she is seeking to
solve, and with a little more experience, he/she will
be able to see in the question the strategy he/she
will use to answer it.

REVIEW ARTICLE

Table 2. Structured and unstructured clinical questions.

Structured

Unstructured

Example

Characteristics

In patients with multiple myeloma who
start chemotherapy with Lenalidomide,
is the prophylactic use of enoxaparin at
60mg SC* every 24 hours compared to
placebo safe and effective in reducing
the number of venous thromboembolic
events at one month of treatment?

They are based on the syntax of the PICO
type question.
P: Participants/population
I: Intervention/indication
C: Comparator/control
O: Outcome

They are not based on PICO syntax. But
Which is the best prophylactic for
they are the basis for the formulation of
preventing venous thromboembolism in
structured questions and are the first
patients with multiple myeloma receiving
questions that should be asked and
Lenalidomide in chemotherapy programs?
rephrased with PICO syntax.

Source: Elaborated by the authors *Subcutaneous

Once the research design has been evaluated and
determined, it is important to assess the risk of bias.
This is one of the most important parts of critical
reading, because a bias systematically deviates the
effect found from the true value and would give
us conclusions far from reality, thus avoiding the
existence of clear benefits for the patient. Therefore,
the risk of bias assessment is very important in
clinical trials, since a bias would lead us to provide
the wrong treatment to a patient or that the patient
does not require it and increases the risk of adverse
effects(9). It is important to know that there are
different methodological tools available to assess
this risk of bias based on the research design. Table
3 shows the research designs and methodological
tools that will help in the critical evaluation. These
tools are checklists of relevant sections that the
articles to be assessed should contain based on the
study design. And according to this, studies can be
classified as having a low, moderate or high risk of
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bias. Another way of evaluating articles is based on
the critical reading tools or instruments provided
by the Red CASPe(8), which are very practical and
targeted for each type of design, and which can be
easily downloaded at the following link: https://
www.redcaspe.org/herramientas/instrumentos. We
always recommend using the one that best suits
you, you should also keep in mind that new tools
continue being developed, including PROBAST, a
tool developed for the assessment of the risk of bias
in predictive model studies published in 2019(10). For
observational studies such as case-control, cohort
and cross-sectional studies, we can use the New
Castell-Otawa tool(11). For systematic reviews we can
use the AMSTAR-II tool, which allows us to assess
the risk of bias for this type of study(12). We invite
readers who wish to learn more about the tools for
assessing the risk of bias to review the following
references:(10-13).
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Table 3. Methodological tools for critical reading according to research designs.
Study design

Methodological tools

Clinical trials

Cochrane risk of bias tool

Cohort studies

“New Castell-Otawa”

Case-control study

“New Castell-Otawa”

Cross-sectional studies

“New Castell-Otawa”

Systematic reviews

AMSTAR II

Prognostic studies

PROBAST

Source: Elaborated by the authors

Once the risk of bias has been assessed, the validity
of the article is determined and therefore, if there is a
need to continue reading or start a new one.

1. The registration of protocols, mainly of systematic
reviews and clinical trials, is of great relevance(14).
For two reasons, the first refers to the evaluation of
the study by the evaluation team of the registries
where it is submitted, providing evidence of the
quality of the study. And second, to compare
the registered protocol with the final article and
evaluate whether all the outcomes defined in
the protocol were reported in the final article,
as well as the congruence with the objectives
and hypotheses. If this congruence is not found,
we could affirm that the results were hidden or
obviated and we are probably facing a problem
of scientific integrity. Currently, the protocols of
observational studies are also being registered,
being in Peru the PRISA database managed by the
National Institute of Health (https://prisa.ins.gob.
pe/).
2. Outcome assessment. Outcomes that are not
clinically relevant for patients are frequently
used. According to the GRADE (Grading of
Recommendations, Assessment, Development
and Evaluation) system, these can be critical
for decision making, as well as important and
noncritical(15). What is important is that the
outcomes, whether primary (main objective of
the study) or secondary (secondary objectives
of the study), are clinical outcomes. In clinical
epidemiology, the clinical outcomes are 5: death,
disease, discomfort, disability, dissatisfaction(16).
As an additional outcome, it is proposed to
add poverty, since the disease has economic
consequences for the patient(16). Intermediate
or surrogate outcomes are frequently used,

Published by INICIB-URP, 2021

3. When planning a clinical study, there must always
be consistency and coherence between the
clinical question, objective and hypothetical(17).
Similarly, when the study is published, this
consistency and coherence should be maintained,
in particular between methods, statistical tests
and conclusions. This axis must not be changed
or diverted from the objective of the study. For
instance, if we want to evaluate the effectiveness
of folic acid plus iron compared to folic acid for
reducing the symptoms of symptomatic anemia
after immunotherapy in patients with primary
autoimmune hemolytic anemia, the conclusion
should give us a reason why the measure taken
is the most efficient. And for no reason should it
give us a different conclusion. If this inconsistency
is detected, the study is unlikely to yield clear
results, the risk of bias is high, and in this case we
are facing a publication bias.
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We share some key points for the general assessment,
which will help to provide a more exhaustive review:

such as blood pressure, glucose levels, tumor
diameter, hemoglobin level, among others that
are not necessarily related to clinically important
outcomes such as death and the others listed
above. Efforts should be made to evaluate
clinically relevant outcomes, especially mortality,
since they bring notable benefits to patients.

4. Evaluate sample size and selection. A robust
study with adequate inferences close to the
true effect is based on probability samples and
adequate sample sizes(18). The inclusion of an
excessive number of subjects makes the study
more expensive. In addition, a study with an
insufficient sample size will estimate a parameter
with low precision or will be unable to detect
differences between groups, leading to erroneous
conclusions(18). The lack of sample size and sample
selection described in the article implies that the
patients were chosen for convenience, limiting
the applicability of the results and restricting their
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use only to the population in which they were
performed.

HOW
WE
ASSESS
OUTCOMES:
CLINICAL RELEVANCE AND IMPACT
The new findings and contribution to knowledge
are found in the outcome section(19). Once we have
determined the validity of the study, it is necessary
to assess the outcomes. In this evaluation, we
recommend that it be done in three steps:
1. What were the outcomes?
2. What is the clinical impact of the outcomes?

REVIEW ARTICLE

3. Clinical relevance of the outcomes?
It is important to observe what the outcomes of the
different studies were. Table 1 summarizes the most
important statistical tests based on the research
design for each type of question. We would like to
emphasize that, for intervention studies, which are
the most frequently consulted on the web, the most
frequently used measures to assess the magnitude
of the effect are relative risks (RR). These are easily
interpreted: if it is greater than 1, the intervention is
associated with an increased risk compared to the
control group; if it is equal to 1, it makes no difference
compared to the control group; and if it is less than
1, the intervention is protective compared to the
control group. Subsequently, we must evaluate
the confidence interval, which is generally framed
within a range with a confidence level of 95%. If the
unit is included within this range of values, the RR
is statistically not significant(20). Similarly, we must
determine the strength of association, whether it is
strong or very strong. When the RR is greater than 5
or less than 0.2, the association is very strong. When
the RR is greater than 2, or less than 0.5, it is strong(15).
The problem arises when these values are less than
2 or greater than 0.5, here the clinical relevance and
expertise of the physician is important to determine
whether these small changes are important for the
patient's health.
This step is relevant, because not only the presence
of association must be evaluated. But also the
magnitude of this association. Among the most
important measures, we have Cohen's Delta, a
measure used to evaluate the effect size in studies
comparing independent groups with quantitative
outcomes (means). For example, in a clinical trial
where they want to evaluate the effect of a new drug
compared to no treatment for raising the hemoglobin
level in patients with sepsis, here the main outcome
https://inicib.urp.edu.pe/rfmh/vol21/iss3/20
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is the hemoglobin level (continuous quantitative
variable). And to detect the effect, they will use a
mean difference between the two groups with their
respective 95% confidence interval (if the confidence
interval includes zero, then it will not be statistically
significant). However, it is important to quantify the
magnitude of the effect. This is where Cohen's Delta
comes into play, and when calculated as 0.8 (0.2:
small; 0.5: medium and 0.8: large), it reveals that the
effect size of the drug to increase hemoglobin is
strong and can be considered for decision making21.
In the following link we share a web application in
which it is possible to calculate Cohen's Delta (https://
www.socscistatistics.com/effectsize/default3.aspx).
For correlation studies, Pearson's R is used, which
indicates whether the correlation is strong, moderate
or low. We recommend the following link so that
you can go deeper into the evaluation of the effect
size for the most important measures of association
( h t t p s : / / w w w. a c a d e m i a . e d u / 4 2 0 1 1 0 2 5 / 5 . _
Estad%C3%ADstica_-_Tama%C3%B1o_de_efecto).
The third and final step is to evaluate clinical relevance
over statistical significance. The relevance depends
on the magnitude of the difference, the seriousness
of the problem to be investigated, the vulnerability,
the morbidity and mortality generated by it, its
cost and its frequency, among other elements(22).
It is recommended that in order to consider the
usefulness of an intervention in clinical practice,
the minimum difference between groups should be
10% of direct superiority to the other(25,23). However,
relative risk reductions of 50% almost always and
25% frequently are considered to be clinically
relevant regardless of statistical significance(22). It is
interesting to note that clinical expertise and the
physician's knowledge of the disease come into
play here. We recommend evaluating the evidence
also on the basis of the differences between the
number of cases in the different groups. As an
example we will take the application of a new drug
to increase the number of platelets in patients with
thrombocytopenic purpura refractory to treatment
compared to Rituximab. After administration, we
evaluated how the number of platelets increased
between the two groups, and we can see that those
who received the new drug increased platelets by
50,000 compared to Rituximab, which only increased
platelet levels by 20,000. However, the group sizes
are small, 30 for the new treatment group and 28
for the Rituximab group. Because of the sample size,
the statistical significance is most likely null, but here
we observe something important, which is clinically
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relevant, because a platelet elevation as achieved by
the new treatment is important for a patient with
chronic thrombocytopenic disease and brings about
remarkable improvements, compared to Rituximab
which did not achieve that level, and the results can
be used for decision making. This is done on the
basis of clinical expertise.

HOW WE APPLY THE OUTCOMES:
APPLICATION TO THE PATIENT

Here we present some steps based on our experience
and on the published literature previously cited in
this article in order to be able to apply in the most
judicious way the results in our patient.
1. Compare and corroborate that the selection
criteria (inclusion and exclusion criteria) of the
study that we have critically read are present in
our patient.
2. Sex and age, evaluate whether these two
variables are present in our patient, In other
words, we will not be able to apply the results of
studies performed in women over 60 years of age
to a 30-year-old male patient. If it is a study that
includes both populations, it is best to evaluate
the effect in the subgroup of gender and age of
our patient.

Authorship contributions: The authors participated
in the genesis of the idea, project design, data
collection and interpretation, analysis of results and
preparation of the manuscript of this research work.
Financing: Self-financed.

4. Severity of the disease, also being one of the most
important criteria, because the severity of the
disease has a great impact on the prognosis of the
patient's disease, and interventions performed
in patients of greater severity will not necessarily
have similar results in patients of lesser severity,
thus the relevance of evaluating this important
aspect in the population.
In summary, ideally, the study population should
be as similar as possible to our patients. However, in
daily practice, this is very difficult to achieve. Because
of this, the application of the outcomes should be as
cautious and responsible as possible and should be
based on populations similar to our patients, with
evaluation of clinically important outcomes.

CONCLUSION
Critical reading of clinical studies is essential for the
resident physician. Its status in this country, which
must probably be deficient as has been the case in
other countries, is still unknown. Structured reading
of clinical evidence should be inculcated during
practical training, since it is largely neglected during
hospital training. We hope that these practical bases
for the critical reading of clinical studies will be
useful for residents of different clinical specialties in
the country.
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There is no general rule that allows us to decide
whether the outcomes of an investigation are
directly applicable to a specific patient. There is a
degree of variability that limits us and makes us take
the evidence for decision-making very carefully.

3. Risk factors, it is necessary to evaluate whether
the risk factors of the population studied are the
same risk factors that our patient has.
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